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Introduction
In about 80% of the population, a  small degree 
of tricuspid insufficiency occurs and therefore is con-
sidered almost physiological [1]. Higher mortality has 
been described among patients with moderate and se-
vere tricuspid regurgitation compared to patients with-
out it, irrespective of the pulmonary pressure value or 
systolic function of the left and right ventricle [2–4]. 
A fourfold increase in the risk of substantial tricuspid 
regurgitation is caused by the presence of the endocar-
dial lead [5].
A chest X-ray examination is used in order to assess 
the position of the lead in the heart [6]. The influence of 
endocardial lead position in the chest X-ray on tricuspid 
valve function and the presence of its insufficiency has 
not yet been described in the literature.
Aim
The aim of the study was to determine the correlation 
between the radiological endocardial lead position and 
the tricuspid valve regurgitation severity.
Material and methods
The study comprised 100 consecutive, random pa-
tients who were admitted to the outpatient clinic be-
tween November 2013 and September 2014 for a routine 
follow-up after cardiac stimulation system implantation. 
There were no data available about their pre-implanta-
tion echocardiographic examination or the lead position 
directly after implantation.
Inclusion criteria: patient after cardiac stimulation 
system implantation; and, conscious consent for the trial.
Exclusion criteria: severe mitral valve insufficiency 
and mitral valve prosthesis.
The patient’s chest X-ray was taken in the poste-
ro-anterior (PA) and lateral position, and transthoracic 
echocardiography was performed.
The authors introduced the definitions of optimal and 
non-optimal lead position.
An optimal lead position in the PA radiological picture 
was defined as its free transition through the right heart 
chambers and through the tricuspid valve as an arch with 
its curve facing the diaphragm.
An excessive lead length was defined as its dou-
ble-crossing through the valve or creating a  loop at the 
valve level (Figure 1 A), transition of two parallel leads 
through the valve creating an expansion mechanism (Fig-
ure 1 B), or excessive lead length in the right atrium with 
the lead loop surrounding the inferior wall of the atrium 
and creating an arch facing upright at the tricuspid valve 
level (Figure 1 C).
Insufficient lead length was defined as excessive 
strengthening of the lead at the tricuspid valve level, 
with stiff, linear passage between the lead tip and the 
right atrium entrance (Figure 1 D).
Radiological assessment of the lead position was 
performed by two doctors performing implantation 
procedures for over 5 years – not optimal lead position 
was recognized at their consensual opinion. Echocardio-
graphic examination evaluated:
–  tricuspid valve function, with severe regurgitation de-
fined according to the ESC guidelines [7];
–  mitral valve function;
–  heart chambers’ diameters: left ventricle end diastolic 
diameter (LVEDd); end diastolic right ventricle diam-
eter (RVEDd) (in parasternal longitudinal view – 1, in 
a four-chamber apical view: at heart base – 2; at chor-
dae tendineae attachment – 3, in longitudinal axis – 4); 
size of both atria (left atrium – LA; right atrium – RA);
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–  left ventricle systolic function (LVEF) (left ventricle ejec-
tion fraction with Simpson method); and
–  left ventricle diastolic function (E/A assessment).
The end point of the study was confirmation of se-
vere tricuspid regurgitation.
Patients were divided into two groups: group A  – 
presence of severe tricuspid regurgitation; group B – ab-
sence of severe tricuspid regurgitation.
The two groups were compared according to the de-
mographic, clinical, echocardiographic, and stimulation 
system technical parameters.
Analyzed parameters were: demographic: age, gen-
der; clinical: heart failure symptoms according to NYHA 
classification and/or physical examination, comorbidities 
(coronary artery disease, arterial hypertension, diabetes 
mellitus); echocardiographic: LVEDd, RVEDd, LA, RA, E/A, 
LVEF, valvular disorders; and technical: number of leads, 
number of leads passing through the tricuspid annulus, 
site of right ventricle stimulation (right ventricle apex 
– RVA; right ventricle outflow tract – RVOT; cardiac re-
synchronization therapy – CRT), presence of an ICD lead, 
time since implantation.
In both groups, the radiological picture of the lead 
passage through the tricuspid valve was analyzed.
Statistical analysis
In order to perform all the calculations, StatSoft 
Inc. (2014) Statistica (data analysis software system) 
Figure 1. Chest X-ray: A–C: An excessive lead length (A – its double-crossing through the valve or creating 
a loop at the valve level, B – transition of two parallel leads through the valve creating the expansion mech-
anism, C – excessive lead length in the right atrium with the lead loop surrounding the inferior wall of the 
atrium and creating an arch facing upright at the tricuspid valve level). D – Insufficient lead length: excessive 
strengthening of the lead at the tricuspid valve level, with stiff, linear passage between the lead tip and the 
right atrium entrance
C
A
D
B
Anna Rydlewska et al. Tricuspid regurgitation related to endocardial leads
167Advances in Interventional Cardiology 2017; 13, 2 (48)
version 12 was used. For the continuous parameters, 
the mean value and standard deviation were calculat-
ed. For the qualitative parameters, the absolute and 
percentage number of cases in relation to the whole 
group was presented. For the continuous values, the 
Shapiro-Wilk W  test was used to verify whether the 
parameter has a  normal distribution. To compare the 
two samples of quantitative parameters, Student’s 
t-test for independent samples was performed. In the 
case of a  non-normal distribution, the non-paramet-
ric Mann-Whitney U  test was performed. The c2 test 
was used in order to compare the qualitative param-
eters; in case of a low number, Fisher’s exact test was 
used. Univariate and multivariate analysis of factors 
influencing severe tricuspid regurgitation was per-
formed. Using logistic regression, multivariate anal-
ysis was performed for those data which reached 
p < 0.1 in univariate analysis. Multivariate analysis was 
performed by the backward stepwise selection method; 
p < 0.05 was defined as statistically significant.
Results
The study included 100 consecutive patients (34 fe-
males, 66 males), mean age of 67.1 ±14 years. Sixty-six 
patients had a pacemaker (PM) implanted, 27 had an im-
plantable cardioverter-defibrillator (ICD), 1 had a  pace-
maker with resynchronization therapy (CRT-P), and 
6 had a cardioverter-defibrillator with resynchronization 
therapy (CRT-D). The mean time from implantation was 
9 years (1–30 years).
In the whole population, severe tricuspid regurgita-
tion was diagnosed in 28 (28%) patients; mean age: 71.0 
±16.0 years; 9 women – group A. Group B comprised 
72 patients aged 65.6 ±13.1 years, 25 women without 
severe tricuspid regurgitation (Table I).
Time from implantation did not differ between 
groups. The total number of leads per patient was higher 
in group B, although the number of leads crossing through 
the tricuspid valve was comparable between groups. The 
higher total number of leads in group B may be the result 
of the larger number of double-chamber stimulators and 
CRT systems in this group. In both groups, the number of 
ICD leads was comparable (28.9% in group A vs. 34.7% 
in group B).
Patients in group A had larger diameters of the right 
ventricle and both atria. The groups did not differ signifi-
cantly for other analyzed criteria (Table I).
Radiological signs of non-optimal lead position were vi-
sualized in 20 (71.4%) patients in group A, and 12 (16.7%) 
patients in group B.
As shown in Table I, radiological signs of non-optimal 
lead position were significantly more frequent in group 
A compared to group B (p < 0.0001). In patients without 
regurgitation, systems assuring atrioventricular and in-
traventricular synchronization (DDD and CRT) were used 
significantly more often.
Multivariate analysis showed that factors influencing 
severe tricuspid regurgitation were as follows: insuffi-
cient lead length (OR = 3.914; p = 0.003) or excessive 
lead length (OR = 2.595; p = 0.017) in the radiological 
picture; enlarged right ventricle in four-chamber view 
(OR = 1.205; p = 0.047); and enlarged right atrium (OR = 
1.175; p = 0.001).
Discussion
Tricuspid valve regurgitation is an insidious disease 
because most often it is (as in most of our population) 
asymptomatic [8, 9].
The mechanisms of tricuspid regurgitation after im-
plantation of endocardial leads have not yet been ful-
ly discovered. Presently, prospective studies are being 
carried out in order to answer the question how endo-
cardial leads influence the tricuspid valve [10]. It was 
hypothesized that systolic dyssynchrony resulting in 
negative ventricle remodeling and tricuspid annulus di-
lation may explain the more frequent occurrence of re-
gurgitation in the case of apical stimulation or impaired 
diastolic left ventricle function [11, 12]. In our study, 
neither stimulation site nor left ventricle systolic func-
tion significantly influenced tricuspid regurgitation.
Other theories have suggested that tricuspid regur-
gitation may be caused by the mechanical influence of 
the lead on the tricuspid apparatus [11, 13]. In this case, 
a higher rate of lesions would be expected in patients 
with ICD leads or a large number of leads. In our material, 
as in the study by Al-Bawardy et al., this relation was not 
proved [4].
Tricuspid valve function also depends on the lead 
curves as it passes through the valve. In the available 
literature, we did not find a study correlating the radio-
logical and echocardiographic picture after implantation 
of the stimulation system. We used novel definitions of 
excessive and insufficient lead length in the radiological 
chest picture, which was altogether named a “non-opti-
mal radiological lead position”.
In our population, insufficient lead length was asso-
ciated with higher risk of tricuspid regurgitation than its 
excessive length. It seems that a stretched lead “holding” 
the tricuspid leaflet has higher risk of causing regurgita-
tion than excessive lead loops inside the valve. 
Patients who were admitted to the study were, by 
definition, asymptomatic, presenting for a  routine fol-
low-up at different times since implantation. Therefore, 
it is impossible to determine whether the observed ra-
diological changes were present since implantation or 
developed over time. And it is not only a limitation of the 
study, but also reflects a true follow-up condition, where 
there are no indications to perform chest X-ray in asymp-
tomatic patients.
Patients with known pre-procedural tricuspid regur-
gitation were not admitted to the study. However, lack 
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Table I. Comparison of demographic, clinical, radiological, and echocardiographic parameters
Parameter Group A Group B P-value Total
Number of patients 28 72 – 100
Age, mean ± SD [years] 71.0 ±16.0 65.6 ±13.1 0.0193 67.1 ±14.1
Time since implantation, mean ± SD [years] 9.96 ±6.20 8.62 ±5.92 0.2450 9.00 ±6.00
Total number of leads per patient, mean ± SD 1.54 ±0.58 1.90 ±0.61 0.0072 1.80 ±0.62
DDD/CRT 15/28 56/72 0.0166 71/100 (71.0%)
ICD 7/28 25/72 0.3494 32/100 (32.0%)
RVA stimulation (%) 19/28 (67.9%) 38/72 (52.8%) 0.2532 57/100 (57.0%)
RVOT and CRT stimulation (%) 9/28 (32.1%) 34/72 (47.2%) 0.2532 43/100 (43.0%)
Excessive lead length in X-ray 8/28 (28.6%) 8/72 (11.1%) 0.0325 16/100 (16.0%)
Insufficient lead length in X-ray 12/28 (42.8%) 4/72 (5.6%) < 0.0001 16/100 (16.0%)
Excessive or insufficient lead length in X-ray 20/28 (71.4%) 12/72 (16.7%) < 0.0001 32/100 (32.0%)
Heart failure symptoms (%) 6/28 (21.4%) 8/72 (11.1%) 0.3105 14/100 (14.0%)
LVEF, mean ± SD (%) 46.3 ±18.4 48.9 ±18.2 0.4055 48.2 ±18.2
LVEDd, mean ± SD [mm] 54.2 ±7.3 55.8 ±9.2 0.5668 55.3 ±8.7
RVEDd1, mean ± SD [mm] 33.6 ±6.0 28.5 ±4.0 < 0.0001 30.0 ±5.2
RVEDd2, mean ± SD [mm] 46.5 ±8.8 39.0 ±7.7 0.0001 41.1 ±8.7
RVEDd3, mean ± SD [mm] 29.0 ±7.9 25.5 ±5.5 0.0288 26.4 ±6.4
RVEDd4, mean ± SD [mm] 64.2 ±7.8 57.1 ±9.1 0.0001 59.1 ±9.3
LA, mean ± SD [mm] 52.5 ±8.1 45.2 ±5.2 < 0.0001 47.2 ±7.0
RA1, mean ± SD [mm] 57.7 ±9.4 44.5 ±6.9 < 0.0001 48.2 ±9.7
RA2, mean ± SD [mm] 57.7 ±10.3 44.5 ±6.3 < 0.0001 48.2 ±9.6
E/A, mean ± SD 1.13 ±0.74 1.18 ±0.86 0.6684 1.17 ±0.83
Coronary artery disease (%) 12/28 (42.9%) 24/72 (33.3%) 0.3730 36/100 (36.0%)
Arterial hypertension (%) 19/28 (67.9%) 36/72 (50.0%) 0.1070 55/100 (55.0%)
Diabetes mellitus (%) 9/28 (32.1%) 8/72 (11.1%) 0.0119 17/100 (17.0%)
DDD/CRT – dual chamber pacing system/cardiac resynchronization therapy, ICD – implantable cardioverter-defibrillator, RVA – right ventricular apex, RVOT – right 
ventricle outflow tract, LVEF – left ventricle ejection fraction, LVEDd – left ventricle end diastolic diameter, RVEDd1 – end diastolic right ventricle diameter in paraster-
nal longitudinal view, RVEDd2 – end diastolic right ventricle diameter in four-chamber apical view at heart base, RVEDd3 – end diastolic right ventricle diameter in 
four-chamber apical view at chordae tendineae attachment, RVEDd4 – end diastolic right ventricle diameter in four-chamber apical view in longitudinal axis, LA – left 
atrium, RA1 – right atrium – longitudinal diameter, RA2 – right atrium – horizontal diameter, E/A – E/A assessment.
of a pre-procedural full echocardiographic study and re-
peated echocardiographic examinations (which are not 
required in a  routine follow-up) made it impossible to 
assess some of the observed changes – enlargement of 
the right heart chambers, or slight changes in tricuspid 
regurgitation level – which is undoubtedly a limitation of 
the study.
Conclusions
Significant tricuspid regurgitation is a common find-
ing in the presence of endocardial leads. Presence of tri-
cuspid regurgitation seems to correlate with non-optimal 
radiological lead position.
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